Geode Capital Management
ALZN icon

Geode Capital Management’s Alzamend Neuro ALZN Stock Holding History

Geode Capital Management’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.4K Buy
45,680
+18,174
+66% +$36.3K ﹤0.01% 4325
2025
Q4 		$50.1K Buy
27,506
+6,928
+34% +$15.7K ﹤0.01% 4232
2025
Q3 		$49K Buy
+20,578
New +$53.4K ﹤0.01% 4300
2025
Q2 		– Sell
-4,350
Closed -$37.1K – 4447
2025
Q1 		$37.1K Buy
4,350
+623
+17% +$5.71K ﹤0.01% 4243
2024
Q4 		$38.9K Buy
+3,727
New +$47.9K ﹤0.01% 4281
2024
Q3 		– Sell
-582
Closed -$21.2K – 4537
2024
Q2 		$21.2K Hold
582
– – ﹤0.01% 4442
2024
Q1 		$52.4K Hold
582
– – ﹤0.01% 4310
2023
Q4 		$48.2K Buy
582
+111
+24% +$18.2K ﹤0.01% 4360
2023
Q3 		$151K Buy
471
+53
+13% +$25.3K ﹤0.01% 4092
2023
Q2 		$287K Hold
418
– – ﹤0.01% 3876
2023
Q1 		$240K Hold
418
– – ﹤0.01% 3952
2022
Q4 		$318K Buy
418
+29
+7% +$42K ﹤0.01% 3858
2022
Q3 		$625K Buy
389
+359
+1,197% +$493K ﹤0.01% 3611
2022
Q2 		$35K Hold
30
– – ﹤0.01% 4852
2022
Q1 		$49K Buy
30
+8
+36% +$15K ﹤0.01% 4806
2021
Q4 		$56K Buy
+22
New +$68.1K ﹤0.01% 4837
2021
Q3 		– Sell
-33
Closed -$389K – 4857
2021
Q2 		$389K Buy
+33
New +$426K ﹤0.01% 4052

Other funds holding ALZN

VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Geode Capital Management's ALZN Position: Q1 2026 in Review

Geode Capital Management increased its Alzamend Neuro (ALZN) stake by 66% in Q1 2026, buying an estimated $36.3K and bringing the position to 45,680 shares worth $48.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4325.

Geode Capital Management first reported a position in ALZN in Q2 2021 and has held it in 17 quarters since. The position peaked at $625K in Q3 2022. 12 funds tracked by Wall St. Rank hold ALZN as of Q1 2026.

  • Geode Capital Management held 45,680 shares of Alzamend Neuro worth $48.4K as of Q1 2026.
  • Geode Capital Management bought 18,174 Alzamend Neuro shares in Q1 2026, an estimated $36.3K.
  • Alzamend Neuro made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4325 holding.
  • Geode Capital Management first reported a position in Alzamend Neuro in Q2 2021 and has held it in 17 quarters since.
  • Geode Capital Management's Alzamend Neuro position peaked at $625K in Q3 2022.
  • 12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.